17 Results for "

Antiproliferative ability

" in MedChemExpress (MCE) Product Catalog:
Products (17)

17 Results for "Antiproliferative ability" in MCE Product Catalog:

Cat. No.: HY-145426
CAS No.: 1817802-18-8
Purity:  98.76%
Target:  

HDAC

Research Areas:  

Cancer

MPT0B390 is an arylsulfonamide-based derivative with potent HDAC inhibitory ability. MPT0B390, TIMP3 inducer, inhibits tumor growth, metastasis and angiogenesis. MPT0B390 shows antiproliferative activity against human colon cancer cell line HCT116 with the GI50 of 0.03 μM .
loading...
    loading...
Cat. No.: HY-168545
SF-1 is an AURKA ligand that can be used for the synthesis of PROTACs, such as PROTAC MPS1 degrader 2 (HY-168543). SF-1 can act as a free inhibitor and has the ability to pull down AURKA, AURKB, and TTK with DC50 values of 273.5, 933.5, and 1274 nM respectively. SF-1 has an anti-proliferative effect on acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-152758
Target:  

Apoptosis Caspase

Research Areas:  

Cancer

Caspase-3/7 activator 3 is an effective activator of Caspase-3/7. Caspase-3/7 activator 3 has tumor selectivity, anti-proliferative activity and high Apoptosis-inducing ability .
loading...
    loading...
Cat. No.: HY-W783415
CAS No.: 1424357-72-1
Target:  

FAK

Research Areas:  

Cancer

STARD3-IN-1 (Compound VS1) is a STARD3 inhibitor with an IC₅₀ of 35 μM. STARD3 is a protein that is overexpressed in various cancers and is involved in cholesterol transport. STARD3-IN-1 exhibits anti-proliferative activity in breast cancer and colon cancer cells, significantly weakening the clonogenic ability of cancer cells. STARD3-IN-1 increases the protein levels of FAK and pTyr397-FAK. STARD3-IN-1 can be used for research on breast cancer and colon cancer .
loading...
    loading...
Cat. No.: HY-168587
Target:  

Drug Derivative

Research Areas:  

Cancer

Antitumor agent-189 (Compound DN4) is a potent antitumor agent, and a 4-oxobutanamide derivative. Antitumor agent-189 inhibits A498 cells proliferation, adhesion and invasion with an IC50 of 1.94 μM. Antitumor agent-189 also inhibits angiogenesis and tumor growth in the xenograft model of A498 cells .
loading...
    loading...
Cat. No.: HY-148265
CAS No.: 1885900-35-5
Purity:  98.76%
Target:  

Microtubule/Tubulin

Research Areas:  

Cancer

Antiproliferative agent-14 (compound 3b) a potent tubulin polymerization inhibitor, with an IC50 of 3.41 μM. Antiproliferative agent-14 has excellent antiproliferative activity. Antiproliferative agent-14 possess the ability to arrest cells at G2/M phases of the cell cycle .
loading...
    loading...
Cat. No.: HY-152748
Target:  

Apoptosis Caspase

Research Areas:  

Cancer

Caspase-3/7 activator 1 is an effective activator of Caspase-3/7. Caspase-3/7 activator 1 has tumor selectivity, anti-proliferative activity and high Apoptosis-inducing ability .
loading...
    loading...
Cat. No.: HY-152756
Target:  

Apoptosis Caspase

Research Areas:  

Cancer

Caspase-3/7 activator 2 is an effective activator of Caspase-3/7. Caspase-3/7 activator 2 has tumor selectivity, anti-proliferative activity and high Apoptosis-inducing ability .
loading...
    loading...
Cat. No.: HY-W040293
CAS No.: 96893-06-0
Synonyms: PE(6:0/6:0); 1,2-Dihexanoyl-sn-glycero-3-phosphoethanolamine
Target:  

Apoptosis

Research Areas:  

Cancer

06:0 PE (PE(6:0/6:0)) is a water-soluble phospholipid characterized by its short acyl chains, exhibiting notable antitumor activity and the ability to inhibit tumor progression in vivo, alongside antiproliferative and proapoptotic effects, while serving as a precursor for phosphatidylcholine and phosphatidylethanolamine.
loading...
    loading...
Cat. No.: HY-173151
BRCA2-IN-1 (Compound 3j) is a potential BRCA2 inhibitor that exhibits antiproliferative activity against the breast cancer MCF-7 cell lines. BRCA2-IN-1 also demonstrates DPPH radical scavenging ability, with an IC50 of 12.36 µM .
loading...
    loading...
Cat. No.: HY-159512
Target:  

EGFR Apoptosis

Research Areas:  

Cancer

EGFR kinase inhibitor 7 (compound 18i) is an EGFR inhibitor (IC50=42.3 nM) with anticancer activity. EGFR kinase inhibitor 7 has significant in vitro cytotoxicity and apoptosis induction ability. EGFR kinase inhibitor 7 has antiproliferative activity against human colon cancer cell line HCT116 and human non-small cell lung cancer cell line A549, with IC50 values ​​of 4.82 µM and 1.43 µM, respectively .
loading...
    loading...
Cat. No.: HY-169400
Research Areas:  

Cancer

HDACs/EZH2-IN-1 (Compound 22a) is a HDACs/EZH2 inhibitor (EZH2 Y641N inhibition rate at 50 nM: 98%), with selective inhibition against HDAC1 and HDAC6 (IC50: 0.23 μM and 0.07 μM, respectively). HDACs/EZH2-IN-1 exerts a antiproliferative effect on diffuse large B-cell lymphoma cells harboring an EZH2 mutation and on various acute myeloid leukemia cells. HDACs/EZH2-IN-1 has the ability to induce cell differentiation and Apoptosis .
loading...
    loading...
Cat. No.: HY-180848
CAS No.: 3051861-49-2
Target:  

Bcl-2 Family Apoptosis

Research Areas:  

Cancer

Bcl-2-IN-24 (Compound 11g) is an efficient and selective Bcl-2 inhibitor with a Kd value of 11.3 μM. Bcl-2-IN-24 exhibits anti-proliferative activity against HCT-116 cells and A549 cells. Bcl-2-IN-24 effectively inhibits the colony-forming ability of tumor cells and induces cell apoptosis. Bcl-2-IN-24 can be used for research on colon cancer and lung cancer .
loading...
    loading...
Cat. No.: HY-W040293S
Synonyms: PE(6:0/6:0)-d22; 1,2-Dihexanoyl-sn-glycero-3-phosphoethanolamine-d22
06:0 PE-d22 (PE(6:0/6:0)-d22) is the deuterium labeled 06:0 PE (HY-W040293). 06:0 PE (PE(6:0/6:0)) is a water-soluble phospholipid characterized by its short acyl chains, exhibiting notable antitumor activity and the ability to inhibit tumor progression in vivo, alongside antiproliferative and proapoptotic effects, while serving as a precursor for phosphatidylcholine and phosphatidylethanolamine.
loading...
    loading...
Cat. No.: HY-182789
Target:  

VEGFR CDK

Research Areas:  

Cancer

VEGFR2-IN-86 is a dual VEGFR2/CDK2 inhibitor, with an IC50 of 0.06 μM against VEGFR2 and an IC50 of 0.78 μM against CDK2. VEGFR2-IN-86 induces G-phase cell cycle arrest, reduces colony-forming ability and tumor cell migration capacity, and exerts antiproliferative activity in cancer cells. VEGFR2-IN-86 can be used for the research of breast cancer and prostate cancer .
loading...
    loading...
Cat. No.: HY-180193
CAS No.: 3105435-06-8
Research Areas:  

Cancer

Tubulin polymerization-IN-86 (Compound B6) is an effective inhibitor of tubulin polymerization. Tubulin polymerization-IN-86 effectively inhibits microtubulin polymerization by binding to the colchicine binding sites on microtubulin, thereby disrupting the microtubule cytoskeleton within the cell. Tubulin polymerization-IN-86 exhibits potent anti-proliferative activity against a variety of cancer cell lines. Tubulin polymerization-IN-86 induces cell cycle arrest, apoptosis, inhibits cell migration, invasion, and long-term survival ability. Tubulin polymerization-IN-86 inhibits tumor growth in mice and can be used for the study of melanoma .
loading...
    loading...
Cat. No.: HY-183783
Target:  

PROTACs RET STAT ERK Apoptosis

Research Areas:  

Endocrinology Cancer

PROTAC RET Degrader 2 is a RET degrader with a target IC50 of 0.36 nM. PROTAC RET Degrader 2 is mainly composed of RET-IN-34 (HY-183729) and Thalidomide (HY-14658). PROTAC RET Degrader 2 mediates RET degradation via the ubiquitin-proteasome system. PROTAC RET Degrader 2 induces apoptosis, inhibits colony-forming ability, and exhibits antiproliferative activity in cancer cells. PROTAC RET Degrader 2 suppresses tumor growth in xenograft models. PROTAC RET Degrader 2 can be used in research related to medullary thyroid carcinoma, papillary thyroid carcinoma, and RET fusion-positive lung adenocarcinoma .
loading...
    loading...
  • 1